| Literature DB >> 33521705 |
Joseph D Feuerstein1, Mohammad Bilal1, Tyler M Berzin1, Audrey H Calderwood2, Praveen Guturu3, Anna C Juncadella4, Gyanprakash Ketwaroo5, Daniel S Mishkin6, David G Perdue7, Sandeep Sekhon8, Neil Sengupta9, Shailendra Singh10, Douglas K Pleskow1, Mandeep S Sawhney1.
Abstract
BACKGROUND AND AIMS: As the COVID-19 pandemic moves into the postpeak period, the focus has now shifted to resuming endoscopy services to meet the needs of patients who were deferred. By using a modified Delphi process, we sought to develop a structured framework to provide guidance regarding procedure indications and procedure time intervals.Entities:
Keywords: COVID-19; Delphi; Endoscopy; Gastroenterology
Year: 2020 PMID: 33521705 PMCID: PMC7836933 DOI: 10.1016/j.tige.2020.12.005
Source DB: PubMed Journal: Tech Innov Gastrointest Endosc ISSN: 2590-0307
List of final EGD indications and interval recommendations.
| Indication | Agreed critical PIO | Time-sensitive Emergent (within 1 week) [%] | Time-sensitive Urgent (within 8 weeks) [%] | Can defer to > 8 weeks (Not time-sensitive) [%] |
|---|---|---|---|---|
| Symptoms | ||||
| Abnormal imaging suggestive of malignancy | Avoidance of cancer / avoidance of cancer progression | 25 | 75 | 0 |
| Acute iron deficiency anemia needing hospitalization or transfusions | Avoidance of death / prolongation of life | 16.7 | 66.7 | 16.7 |
| Bravo pH probe placement | Other: diagnosis and treatment, prevent morbidity, symptom control | 0 | 0 | 100 |
| Chest pain | Improvement or palliation of symptoms | 0 | 16.7 | 83.3 |
| Chronic anemia / Iron deficiency anemia | Avoidance of death / prolongation of life | 0 | 33.3 | 66.7 |
| Diarrhea | Improvement or palliation of symptoms | 0 | 25 | 75 |
| Duodenal stenting for duodenal / pancreatic cancer | Improvement or palliation of symptoms | 75 | 25 | 0 |
| Dyspepsia / Epigastric pain | Improvement or palliation of symptoms | 0 | 16.7 | 83.3 |
| Dysphagia | Improvement or palliation of symptoms | 16.7 | 75 | 8.3 |
| Early satiety | Avoidance of death / prolongation of life | 0 | 84.6 | 15.4 |
| Esophageal cancer stenting | Improvement or palliation of symptoms | 58.3 | 41.7 | 0 |
| Esophageal food impaction | Avoidance of major surgery and/or hospitalization | 100 | 0 | 0 |
| Esophageal narrowing / stenosis needing treatment | Improvement or palliation of symptoms | 16.7 | 66.7 | 16.7 |
| Foreign body removal | Avoidance of major surgery and/or hospitalization | 100 | 0 | 0 |
| Gastric polyp | Avoidance of cancer / avoidance of cancer progression | 0 | 8.3 | 91.7 |
| GERD | Other: diagnosis and treatment, prevent morbidity, symptom control | 0 | 8.3 | 91.7 |
| GI bleeding / hematemesis/ melena | Avoidance of death / prolongation of life | 100 | 0 | 0 |
| Nausea and vomiting (daily/persistent) | Improvement or palliation of symptoms | 7.7 | 92.3 | 0 |
| Nausea and vomiting (intermittent) | Improvement or palliation of symptoms | 0 | 15.4 | 84.6 |
| PEG tube placement | Improvement or palliation of symptoms | 0 | 61.5 | 38.5 |
| Unexplained weight loss | Avoidance of death / prolongation of life | 0 | 76.9 | 23.1 |
| Screening / Surveillance | ||||
| Barrett's esophagus surveillance (non-dysplastic) | Avoidance of cancer / avoidance of cancer progression | 0 | 0 | 100 |
| Barrett's esophagus with LGD | Avoidance of death / prolongation of life | 0 | 16.7 | 83.3 |
| Barrett's esophagus with HGD | Avoidance of death / prolongation of life | 0 | 66.7 | 33.3 |
| Celiac disease | Improvement or palliation of symptoms | 0 | 0 | 100 |
| Duodenal adenoma without high grade dysplasia | Avoidance of cancer / avoidance of cancer progression | 0 | 8.3 | 91.7 |
| Duodenal adenoma with high grade dysplasia of intra-mucosal cancer | Avoidance of cancer / avoidance of cancer progression | 0 | 91.7 | 8.3 |
| Eosinophilic Esophagitis (EoE) surveillance | Avoidance of major surgery and/or hospitalization | 0 | 15.4 | 84.6 |
| Esophageal varices for primary prophylaxis | Avoidance of death / prolongation of life | 0 | 25 | 75 |
| Esophageal varices for secondary prophylaxis | Avoidance of death / prolongation of life | 0 | 75 | 25 |
| Follow-up of gastric ulcer | Avoidance of death / prolongation of life | 0 | 7.7 | 92.3 |
| Gastric intestinal metaplasia | Avoidance of death / prolongation of life | 0 | 0 | 100 |
| Helicobacter Pylori | Avoidance of death / prolongation of life | 0 | 8.3 | 91.7 |
Procedural indications in which consensus was not achieved on first vote and were subject to re-vote
Procedural indications in which consensus was not achieved after discussion and re-vote
Procedural indications which were sub-classified based on discussion and feedback from expert panel
List of final colonoscopy indications and interval recommendations.
| Indication | Agreed critical PIO | Time-sensitive Emergent (within 1 week) [%] | Time-sensitive Urgent (within 8 weeks) [%] | Can defer to > 8 weeks (Not time-sensitive) [%] |
|---|---|---|---|---|
| Symptoms | ||||
| Abdominal pain | Improvement or palliation of symptoms | 0 | 8.3 | 91.7 |
| Abnormal imaging suggestive of malignancy | Avoidance of death / prolongation of life | 16.7 | 66.7 | 16.7 |
| Bloody diarrhea / bright red blood per rectum | Avoidance of cancer / avoidance of cancer progression | 0 | 92.3 | 7.7 |
| Change In bowel habits | Avoidance of death / prolongation of life | 0 | 33.3 | 66.7 |
| Colon stricture dilation | Improvement or palliation of symptoms | 33.3 | 66.7 | 0 |
| Constipation | Improvement or palliation of symptoms | 0 | 8.3 | 91.7 |
| Diarrhea (chronic) | Other: diagnosis and treatment, prevent morbidity, symptom control | 0 | 8.3 | 91.7 |
| Endoscopic mucosal resection (EMR) of colon polyp | Avoidance of death / prolongation of life | 0 | 33.3 | 66.7 |
| Follow up of diverticulitis | Avoidance of cancer / avoidance of cancer progression | 0 | 8.3 | 91.7 |
| Graft versus host disease evaluation | Other: Change in management with confirmation of GVHD | 7.7 | 92.3 | 0 |
| Heme positive stool | Avoidance of cancer / avoidance of cancer progression | 0 | 23 | 77 |
| Iron deficiency anemia / symptomatic anemia | Avoidance of cancer / avoidance of cancer progression | 0 | 92.3 | 7.7 |
| Lower gastrointestinal bleed | Avoidance of death / prolongation of life | 46.1 | 53.9 | 0 |
| Obstruction / needing colon stent | Avoidance of major surgery and/or hospitalization | 83.3 | 16.7 | 0 |
| Pseudo-obstruction | Perforation / death and preventing emergent surgery | 83.4 | 8.3 | 8.3 |
| Sigmoid volvulus | Avoidance of major surgery and/or hospitalization | 100 | 0 | 0 |
| Unexplained weight loss | Avoidance of cancer / avoidance of cancer progression | 0 | 46.1 | 53.9 |
| Screening / Surveillance | ||||
| Colitis / Inflammatory Bowel Disease surveillance | Avoidance of death / prolongation of life | 0 | 16.7 | 83.3 |
| Colorectal cancer screening | Avoidance of death / prolongation of life | 0 | 0 | 100 |
| Colorectal cancer surveillance, history of colon polyps, and post endoscopic mucosal resection surveillance | Avoidance of cancer / avoidance of cancer progression | 0 | 8.3 | 91.7 |
| Fecal immunohistochemical testing/Positive Cologuard | Avoidance of death / prolongation of life | 0 | 33.3 | 66.7 |
Procedural indications in which consensus was not achieved on first vote and were subject to re-vote
Procedural indications in which consensus was not achieved even after discussion and re-vote. +Procedural indications which were sub-classified based on discussion and feedback from expert panel
List of final flexible sigmoidoscopy indications and interval recommendations.
| Indication | Agreed critical PIO | Time-sensitive Emergent (within 1 week) [%] | Time-sensitive Urgent (within 8 weeks) [%] | Can defer to > 8 weeks (Not time-sensitive) [%] |
|---|---|---|---|---|
| Symptoms | ||||
| Abnormal CT scan / imaging concerning for malignancy | Avoidance of death / prolongation of life | 16.7 | 75 | 8.3 |
| Anorectal symptoms | Improvement or palliation of symptoms | 0 | 16.7 | 83.3 |
| Colitis flare | Improvement or palliation of symptoms | 16.7 | 75 | 8.3 |
| Colonic pseudo-obstruction | Avoidance of death / prolongation of life | 66.7 | 25 | 8.3 |
| Diarrhea | Improvement or palliation of symptoms | 0 | 16.7 | 83.3 |
| Rectal bleeding | Avoidance of cancer / avoidance of cancer progression | 0 | 61.5 | 38.5 |
| Pouchitis | Other: Evaluate for pouchitis | 0 | 69.2 | 30.8 |
| Rectal cuff surveillance | Avoidance of cancer / avoidance of cancer progression | 0 | 16.7 | 83.3 |
Procedural indications in which consensus was not achieved on first vote and were subject to re-vote
Procedural indications in which consensus was not achieved even after discussion and re-vote. +Procedural indications which were sub-classified based on discussion and feedback from expert panel
Best practices recommendations regarding time intervals for various procedural indications.
| EGD indications | Colonoscopy indications | Flexible Sigmoidoscopy indications | |
|---|---|---|---|
| - Duodenal stenting for duodenal / pancreatic cancer | - Obstruction / needing colon stent | - Colonic pseudo-obstruction | |
| -Acute iron deficiency anemia needing hospitalizations of transfusions | - Abnormal imaging suggestive of malignancy | - Abnormal CT scan / imaging concerning for malignancy | |
| - Bravo pH probe placement | -Abdominal pain | - Anorectal symptoms |
Procedural indications in which final consensus was not achieved
Steps needed to re-open the endoscopy suites.
| Critical (%) | Important (%) | Helpful but not important (%) | Not needed (%) | |
|---|---|---|---|---|
| Presence of adequate PPE | 100 | 0 | 0 | 0 |
| Point of care testing with rapid results for patients coming in for endoscopy | 66.7 | 25 | 8.3 | 0 |
| Point of care testing with rapid results to check physicians and endoscopy healthcare workers on a daily basis in endoscopy | 38.5 | 38.5 | 23 | 0 |
| Point of care test that indicates if antibodies are present or not | 23.1 | 30.8 | 46.1 | 0 |
| Regional decrease in total number of new COVID-19 positive cases | 61.5 | 38.5 | 0 | 0 |
| Adequate training of staff to screen for COVID-19 and manage suspected COVID-19 patients | 84.6 | 7.7 | 7.7 | 0 |